Lab work, by its very nature, is a quest for results. As you plan your process, you might not even realize how cell separation can impact your outcome. So, don't get halfway through the design of your manufacturing process only to realize that cell separation is exactly what you needed. Take time now to discover the Elutra system's convenient method for separating cell populations into high-purity, high-yield cell products.1,2
From existing DC maturation processes to newer CAR T-cell therapies, cell separation is playing a major role in the fast-growing fields of research and product development. Today, the Elutra system can be the answer when your process requires cell separation.
The Elutra system passes fluid through the cell layer established within a centrifugal field inside the separation chamber. By varying the flow of fluid in the opposite direction to the centrifugal force, the system aligns and collects particles according to size (smallest to largest) and density (lower to higher). Using both size and density as separation factors increases the resolution of cell separation compared to what is achieved with traditional centrifugation.
From existing dendritic cell (DC) maturation processes to newer chimeric antigen receptor (CAR) T-cell therapies, cell separation is playing a major role within these fast-growing fields of research and product development. Today, the Elutra system can be the answer when your process requires high recoveries and purities of monocytes and lymphocytes.
USER CONFIGURABLE PROFILES
INPUT LINE CURRENT
1Read EJ, et al., NIH Department of Transfusion Medicine, Bethesda, MD; Gambro BCT, Lakewood, CO. "Evaluation of a Closed Automated System to Isolate Peripheral Blood Monocytes for Dendritic Cell (DC) Immunotherapy." Ninth annual meeting of the ISCT, 29 May to 1 June 2003.
2Powell DJ, et al., "Efficient Clinical-Scale Enrichment of Lymphocytes for Use in Adoptive Immunotherapy Using a Modified Counterflow Centrifugal Elutriation Program." Cytotherapy 2009; 11 (7): 923–935.
✝Typical results based on cell counts from a leukapheresis product collected the previous day from normal donors on a COBE® Spectra Apheresis System. 80 mL to 230 mL products contained 5 to 14 × 109 WBC count, 80 percent to 100 percent mononuclear cell and 1.8 mL to 4.7 mL red blood cell volume.
Quantum® Cell Expansion System
Products available in select markets.